Clinical Trial Document Management becomes difficult when a study spreads its records across sponsors, CROs, investigator sites, laboratories, technology vendors, and separate clinical systems. A file may exist, yet the study team can still have a document control problem if people can’t confirm which version is current, where the original resides, who changed it, or whether the full history can be produced during an inspection.
That pressure grows as clinical trials use more electronic systems and external service providers. Important records may move through an eTMF, CTMS, eISF, electronic signature platform, email account, quality system, or local site repository before the study closes. Each handoff introduces questions about ownership, metadata, access, version history, and preservation.
Current Good Clinical Practice places greater attention on records that allow trial conduct and the reliability of results to be reconstructed. FDA issued final ICH E6(R3) guidance in September 2025, bringing risk-based thinking and modern technology more clearly into GCP expectations. Clinical teams therefore need document controls that match how studies actually operate rather than relying on an old paper-binder mindset.
Calance’s clinical trial solutions address this wider technology environment through clinical system integration, regulatory and SOP review, analytics, AI-supported workflows, and controlled deployment into platforms such as CTMS and eTMF. The document program still needs clear ownership and operating procedures, because technology can’t compensate for unclear filing decisions or missing accountability.
TL;DR
Clinical Trial Document Management should let an authorized reviewer reconstruct what happened during a study without depending on personal memory or disconnected spreadsheets. That means the trial must know which records are essential, where each record belongs, who controls it, which version is current, how changes are traced, and how records remain readable throughout the required retention period. Site files and sponsor TMFs may differ because the investigator and sponsor have different responsibilities, but the complete record across those repositories must still support GCP review.
The main risk appears when document control is treated as an end-of-study cleanup exercise. Filing needs to happen during trial conduct, audit trails need meaningful review, access rights need control, and archival requirements need to be planned before systems are retired or records are migrated. Retention also can’t be reduced to one global number, because FDA, EU, UK, product-specific rules, and local medical-record requirements can create different obligations.
What Clinical Trial Document Management Covers
Clinical Trial Document Management is the controlled handling of records created or received throughout a clinical study. It covers the point where a record is created, its review and approval, filing location, access permissions, later changes, retrieval, archival, and eventual destruction when permitted.
The scope is wider than an electronic Trial Master File. An eTMF is an important repository, but a clinical study can have essential records in investigator-controlled systems, source-data platforms, safety systems, laboratories, electronic consent tools, quality systems, and other approved locations. A document-management plan therefore needs to identify those systems and describe how records held outside the TMF remain visible to the study team.
| Record Environment | Main Purpose | Typical Control Need |
| Sponsor TMF or eTMF | Sponsor-held essential trial records | Completeness, filing timeliness, metadata, access and oversight |
| Investigator Site File | Investigator and institution records | Site ownership, current approvals, staff records and local documentation |
| Source Records | Evidence supporting participant observations and trial data | Attribution, integrity, investigator control and availability |
| CTMS | Study, site, monitoring and milestone information | Integration, reconciliation and traceability |
| Quality System | Deviations, CAPA, procedures and controlled quality records | Approval history, version control and access |
| Archive | Long-term preservation after closeout | Readability, retrieval, integrity and controlled access |
Technology work around these repositories often involves interfaces and controlled business rules rather than one isolated application. Calance’s application development and automation services include application integration and process automation, which can be relevant when clinical records move between validated or regulated systems.
Clinical data management is related but different. Data management focuses mainly on clinical data collection, cleaning, review, and readiness for analysis. Document management focuses on the records that show how the trial was planned, authorized, conducted, controlled, and closed.
TMF, eTMF, ISF, And Site Files: How The Record Set Fits Together
The Trial Master File and Investigator Site File tell different parts of the same study history. EU Clinical Trials Regulation Article 57 explicitly allows the investigator and sponsor TMFs to have different content when their responsibilities justify the difference. A sponsor therefore shouldn’t expect every investigator-controlled record to be copied into the sponsor repository simply to create a larger file.
The sponsor side commonly holds documents related to trial management, monitoring, vendor oversight, safety communication, study plans, country-level approvals, and sponsor-controlled decisions. The investigator or institution keeps records connected with local conduct, site staff, participant care, local approvals, source records, and other material that should remain under site control.
Some records can be represented in both environments. Others may be held in one approved location with a reference or signpost from another system. The document plan needs to describe that arrangement clearly enough that a monitor or inspector can locate the authoritative record without guessing.
The industry is also working toward better alignment between sponsor and site filing structures. CDISC has published a provisional Investigator Site File Reference Model Version 1.0 that maps to TMF Reference Model v3.3.1. CDISC states that the model is intended to improve consistency in site documentation and reduce filing errors, with later integration planned into the TMF Standard Model.
A useful location register can include:
- Record or artifact type
- Responsible owner
- Authoritative repository
- Sponsor or site responsibility
- Required metadata
- Expected filing point
- Retention rule
- Access restriction
This is also where reporting can help. Calance’s Business Intelligence and Data Science services can support reporting across operational sources when a study needs visibility into document status or connected clinical-system information. Any reporting layer used for regulated oversight still needs clear source definitions and documented controls.
Essential Records Under ICH E6(R3): What Changed
ICH E6(R3) strengthens the idea that essential records should reflect the design and conduct of the actual clinical trial. The final FDA guidance incorporates risk-based approaches and recognizes modern trial designs, technologies, and data sources rather than treating every study as though it follows one fixed operating model.
The practical consequence is important for Clinical Trial Document Management. Teams need to determine which records are essential for their study, where those records will be kept, and how they will remain retrievable. Filing a large volume of low-value material doesn’t fix missing records that are necessary to understand an important trial decision.
FDA’s ICH E6(R3) Good Clinical Practice guidance should therefore sit at the center of the document-management framework. The operating model needs to support records that collectively show how the study was managed, what affected trial conduct, and whether the resulting information can be trusted.
| Older Working Assumption | Better E6(R3)-Aligned Approach |
| Start with a fixed document checklist | Define essential records according to the study and its risks |
| Reconcile heavily near study close | Maintain records while trial activities occur |
| Treat the eTMF as the whole record universe | Map approved repositories across sponsor, site and service providers |
| Measure quality mainly by document count | Examine completeness, timeliness, correctness and retrievability |
| Treat technology validation as a one-time exercise | Control systems according to intended use and associated risk |
The change doesn’t remove the need for structure. It makes the reasoning behind that structure more important. A TMF plan should explain expected records, filing responsibilities, oversight methods, record locations, and how gaps will be identified during the study.
Service-provider arrangements matter as well. A sponsor can transfer trial activities, but oversight responsibilities don’t disappear simply because a CRO or technology provider performs the work. Contracts, procedures, access arrangements, transfer plans, and review records should show how the sponsor remains informed about essential trial activities.
Building And Maintaining Site Files From Startup Through Closeout
A reliable site file starts before site activation. Waiting until monitoring begins often means that staff qualifications, approvals, delegation records, protocol versions, or training evidence must be reconstructed after the activity occurred. That creates extra work and can leave uncertainty about what was in effect at a specific point in the study.
During startup, the investigator site should establish its file structure and identify who can create, review, approve, file, and remove records. The team should confirm how electronic signatures are handled, where source information resides, how sponsor-provided documents enter the site file, and which records must remain under investigator control.
During study conduct, the site file becomes a living history. Protocol amendments, revised consent forms, ethics approvals, updated delegation information, safety communications, monitoring correspondence, and staff changes should be filed according to defined procedures. Superseded material needs to remain distinguishable from the version that later replaced it.
Access security is part of this work. Clinical repositories can contain participant-related information, investigator information, study plans, and records that reveal sensitive operational details. Calance’s Cybersecurity Services include access controls, monitoring, and security support that can be relevant to regulated clinical environments where record exposure needs tight control.
Closeout should reconcile the site file against expected records and unresolved actions. The study team should confirm that missing-document explanations have evidence, outstanding signatures are resolved, final versions are identified, external locations remain accessible, and archive responsibilities have been documented.
A site shouldn’t surrender investigator-controlled records merely because the sponsor is closing its own TMF. Transfer decisions must respect the investigator’s regulatory responsibilities and the agreed location of original records. The closeout plan should also explain who the site contacts if ownership, system access, or archive arrangements later change.
Audit Trails: What Must Be Captured, Reviewed, And Preserved
An audit trail records the history of activity in an electronic system. In a clinical document environment, that history can show when a record was created, uploaded, changed, approved, reclassified, signed, deleted, restored, or viewed where viewing activity is recorded. It can also document changes to metadata and user permissions.
FDA’s guidance for computerized systems describes an audit trail as a secure, computer-generated, time-stamped record that allows reconstruction of events related to creation, modification, and deletion. FDA also states that changes to required records shouldn’t obscure the original information and that relevant audit trails need to be available for inspection.
The current FDA guidance on electronic systems, records, and signatures in clinical investigations provides a more recent reference for sponsors, investigators, IRBs, CROs, and other parties using electronic records in clinical investigations. It addresses the conditions under which FDA considers electronic records and signatures trustworthy and reliable.
A useful audit-trail review looks beyond whether the system technically generates a log.
| Audit Event | What Reviewers Need To Understand |
| Record creation | Who created or uploaded the record and when |
| Modification | What changed and which prior state remains available |
| Deletion | Who performed it, when it occurred and why it was permitted |
| Approval | Which user approved the content and under what workflow |
| Electronic signature | Signer identity, date, time and connection to the signed record |
| Metadata change | Previous value, new value and responsible user |
| Permission change | Who changed access and whether the change matched the user’s role |
| Migration | Whether document history and audit information survived transfer |
Having an audit trail isn’t the end of the control. Teams need a documented approach to reviewing audit information when risk warrants it. A high volume of unusual deletions, repeated metadata changes after finalization, late user deactivation, or unexpected permission changes can reveal a process problem even when all final PDF files appear present.
FDA’s Part 11 scope and application guidance also matters when electronic records are used to satisfy FDA record requirements. The guidance explains FDA’s enforcement approach while making clear that applicable predicate-rule obligations still apply.
The system’s identity and access layer matters because an audit trail only has value when user attribution is credible. Calance’s Microsoft Cloud Consulting services cover identity, governance, security, and Microsoft cloud environments. Those controls can support clinical technology when regulated systems depend on enterprise identity services or connected cloud infrastructure.
Version Control, Certified Copies, Metadata, And Electronic Signatures
Document integrity depends on context as much as file content. Two PDF files can look identical while having different approval histories, metadata, or status within the study. The document program therefore needs controls that preserve the relationship between the content and the information that proves where it came from.
Version control should make the current approved record clear while preserving prior versions when they form part of the study history. Staff shouldn’t overwrite a final document simply because a correction is required. The later version should carry its own history, and the previous state should remain traceable where the recordkeeping requirement calls for it.
Certified copies require similar care. FDA’s computerized-systems guidance defines a certified copy as a copy verified as an exact copy with the same information and attributes as the original. A scanning process therefore needs more than image quality. The organization needs a defined way to confirm completeness and authenticity when a copy replaces the original in the regulated record set.
Metadata should receive the same attention as visible document text. Study number, country, site, artifact type, document date, version, status, and other classification fields affect retrieval and context. Poor metadata can make a complete repository behave like an incomplete one because reviewers can’t reliably locate or group the records they need.
AI can assist with classification, document review, comparison, and extraction, but those uses need controlled boundaries in a regulated environment. Calance’s Generative AI Solutions include intelligent document processing and document review use cases. Human review, validation, source traceability, access control, and clear responsibility remain important when AI touches regulated trial records.
Clinical Trial Document Retention Across The U.S., EU, And UK
Clinical Trial Document Retention should begin with the applicable regulation rather than a company-wide default such as “keep everything for 2 years” or “keep everything for 25 years.” The governing period can depend on jurisdiction, trial type, product status, submission timing, record category, and local requirements for participant medical files.
For U.S. drug investigations, 21 CFR 312.62 requires investigators to retain specified records for 2 years after approval of a marketing application for the investigated indication. If an application isn’t filed or isn’t approved for that indication, the rule provides for retention until 2 years after the investigation is discontinued and FDA is notified. The exact condition matters, so teams shouldn’t reduce the rule to a generic 2-year statement.
The current FDA investigator record-retention requirements should be read alongside the study’s other applicable obligations. Sponsor requirements, device requirements, other record categories, contractual commitments, or separate laws can create additional retention needs.
The EU has a much longer baseline for the clinical TMF. Article 58 of Regulation (EU) No 536/2014 requires the sponsor and investigator to archive the content of the clinical Trial Master File for at least 25 years after the end of the trial unless other Union law requires longer. Medical files follow national law, and any transfer of TMF ownership must be documented.
The EU Clinical Trials Regulation also requires archived TMF content to remain available and accessible to authorities. It says the media used for archiving must preserve completeness and legibility throughout the retention period, while changes to the TMF content must remain traceable.
UK requirements also changed recently. The amended Clinical Trials Regulations took full effect on April 28, 2026. Current MHRA guidance states that essential documents and participant medical files are generally retained for at least 25 years for trials falling under the amended framework, while transitional provisions affect certain trials submitted before the change.
The MHRA guidance on archiving and retention of clinical trial records also discusses named archive responsibility, validated scanning, long-term readability, audit trails, metadata, ownership transfer, and controlled destruction. Those details make the UK guidance useful even for teams that already understand the basic retention period.
| Area | Key Retention Point | Operational Implication |
| U.S. Drug Investigation | Investigator requirements under 21 CFR 312.62 depend on approval or discontinuation conditions | Track the regulatory event that starts the retention clock |
| European Union | TMF content generally retained at least 25 years after trial end | Build long-term archive access and ownership into closeout |
| United Kingdom | Current rules generally require at least 25 years for covered essential records, subject to transitional and other requirements | Confirm application timing and any longer record rule |
| Participant Medical Files | May follow separate national or institutional rules | Don’t assume the TMF period controls every medical record |
| Ownership Transfer | Transfer may move archive responsibility | Document owner, date, location and continuing obligations |
A retention schedule should identify the rule that controls each record category. It should also define who approves destruction and what evidence of destruction must remain. Destroying records because a system contract ended or storage became expensive isn’t an acceptable substitute for applying the controlling retention requirement.
The Document Lifecycle From Creation Through Archival And Destruction
Every essential record has a lifecycle, even when the underlying system hides some of its steps. The record begins when information is created or received, then moves through review, approval, filing, active use, later revision where permitted, closeout, archival, and final disposition.
Archival changes the operating mode of the record, but it doesn’t remove the requirement to preserve context. EMA’s guideline on TMF content, management, and archiving states that the TMF should support document identification, version history, search, retrieval, and direct accessibility for competent authorities. The guidance also addresses both paper and electronic TMFs.
An archive therefore needs to retain more than rendered documents when other information is required to reconstruct their history. Relevant metadata, version information, audit history, links, and records explaining external locations can be part of the usable archive.
System retirement creates a particular risk. A technically successful export can still fail the business requirement if documents lose classifications, relationships, signatures, timestamps, or audit information. Migration testing should therefore prove that authorized users can retrieve and interpret archived records after the original platform is no longer available.
Infrastructure decisions also affect long-term preservation. Calance’s IT Infrastructure and Operations services include cloud and hybrid operations, backup, access controls, recovery, and system support. In a clinical archive, those technical controls need to follow the archive’s approved procedures and retention requirements.
Destruction belongs at the end of the controlled lifecycle. The organization should confirm that no applicable regulation, legal hold, marketing authorization requirement, contract, or institutional obligation requires continued retention. The destruction decision and its authorization should themselves be documented.
Common TMF And Site File Failures Before An Inspection
Most serious document problems don’t begin on the day an inspector arrives. They build gradually when study teams accept small gaps because the missing information appears easy to fix later. By closeout, the people who created the records may have changed roles, vendors may have left, and source systems may already be scheduled for retirement.
| Failure | Why It Matters | Better Control |
| Late filing | Reviewers can’t confirm the record existed when the activity occurred | Track expected filing dates during study conduct |
| Missing approvals | Final status becomes uncertain | Require controlled approval workflows |
| Duplicate final versions | Users can’t identify the authoritative record | Define version and finalization rules |
| Unexplained deletion | Record history may appear incomplete | Preserve deletion reason and audit information |
| Old user access | Former staff may retain inappropriate permissions | Review and revoke access after role changes |
| Missing metadata | Documents become hard to retrieve or interpret | Define mandatory metadata by artifact |
| Broken external links | Referenced records can’t be reached | Test signposts and external locations |
| Incomplete CRO transfer | Sponsor oversight and final archive may have gaps | Define transfer content before study close |
| Lost audit trails | The history of electronic records disappears | Include audit information in migration plans |
| Unreadable archive formats | Records technically exist but can’t be used | Test retrieval and readability over time |
A useful inspection-readiness review asks whether the TMF can tell the study story without explanation from one specific employee. The reviewer should be able to follow key decisions, identify the records supporting them, and understand corrections or later changes.
Automation can help identify missing items or route review tasks, but regulated decisions still need accountable ownership. Calance’s Agentic AI Solutions include workflow agents, document-related actions, audit logging, access controls, and human review for sensitive activities. Those ideas can support controlled clinical workflows when validation and governance requirements are addressed before use.
Inspection readiness works best as an operating condition rather than a short project before an expected authority visit. A study team that checks completeness, access, version history, and unusual audit events during conduct has fewer unknowns when the TMF is frozen or archived.
Clinical Trial Document Management Platforms And Service Partners
Technology selection should start with the operating model. Some organizations need a purpose-built eTMF, while others already have an eTMF and need integration, migration, document intelligence, security work, or compliance support around it. Treating those categories as identical makes provider comparisons misleading.
The right evaluation should consider system ownership, sponsor-to-CRO working arrangements, site connectivity, audit history, metadata portability, inspection access, archive capability, and integration with the wider clinical technology environment.
Calance
Calance is a strong first option for organizations that already use clinical platforms and need engineering, AI, integration, security, analytics, or compliance work around them. Its clinical trial offering includes SOP gap analysis, controlled pilots, validation work, audit trails, and integration with systems such as CTMS or eTMF.
Veeva
Veeva Vault eTMF focuses on sponsor and CRO TMF management with document workflows, visibility, inspection access, TMF health reporting, and trial oversight. Veeva also supports controlled TMF transfer and archival, which can reduce the need for large end-of-study migrations between separate sponsor and CRO environments.
Florence Healthcare
Florence connects sponsor eTMF workflows with site eISF environments. Its current eTMF offering covers site collaboration, document status visibility, remote monitoring, workflows, permissions, and connection with site eBinders, giving sponsors and CROs a direct route into site-level documentation processes.
Trial Interactive
Trial Interactive gives particular attention to eTMF audit trails and the history behind document activity. Its material covers creation, modification, deletion, metadata, permissions, review activity, and export of audit information, which makes it useful for teams that place heavy weight on reconstructing electronic document history.
Phlexglobal
Phlexglobal’s PhlexTMF covers planning, study startup, active TMF management, closeout, inspection, and archive. Its offering also includes TMF services and document classification support, with an emphasis on completeness, filing timing, metadata accuracy, and reducing inspection risk across the file lifecycle.
Montrium
Montrium eTMF Connect includes expected-artifact tracking, version history, audit trails, inspector access, archive functions, site document intake, and a built-in eISF repository. Its feature set places strong weight on real-time completeness and the connection between sponsor TMF oversight and site documentation.
MasterControl
MasterControl connects eTMF document management with wider clinical quality processes. Its clinical offering manages trial records and study activities while linking clinical operations with quality-system functions, which can suit organizations that want TMF controls tied closely to broader regulated quality workflows.
Taimei Technology
Taimei’s eArchives product covers eTMF document creation, approval, filing, quality checks, access, tracking, and archiving. It supports TMF reference structures and connects with Taimei’s CTMS environment, allowing clinical teams to move selected operational records into the eTMF through connected workflows.
No single provider is automatically the right choice for every clinical organization. A sponsor replacing its TMF platform has a different need from a company that wants AI-based document review inside an existing eTMF, and both differ from a CRO that needs sponsor visibility across multiple studies.
How Calance Can Support Clinical Trial Document Management
Calance fits Clinical Trial Document Management where the challenge crosses system boundaries. Its public clinical trial work includes regulatory and SOP gap analysis, clinical analytics, controlled AI deployment, validation activities, user logging, audit trails, security controls, and integration with existing CTMS or eTMF systems.
That distinction matters because many sponsors don’t need another document repository. They need their existing clinical systems to exchange information correctly, maintain controlled workflows, support regulated review, and give teams clearer visibility into document status or compliance gaps.
Calance can also bring document-processing technology into these workflows. Its Generative AI practice includes intelligent document processing, while its clinical trial services describe NLP and large language model use for protocol and SOP analysis. Any use in a regulated workflow should be defined according to intended purpose and supported by appropriate testing, validation, permissions, traceability, and human responsibility.
For organizations reviewing their document environment, the starting point should be the operating problem rather than the tool. Map where essential records live, identify weak handoffs, check audit and archive requirements, then decide whether the gap calls for system configuration, integration, migration, AI-assisted review, security changes, or process redesign.
Frequently Asked Questions
What Is Clinical Trial Document Management?
Clinical Trial Document Management is the controlled handling of records created, received, reviewed, approved, filed, changed, archived, or destroyed during a clinical study. It can cover sponsor TMFs, investigator site records, source-record locations, quality systems, CTMS-generated records, safety documentation, and other approved repositories.The purpose is to maintain records that allow authorized reviewers to understand how the trial was planned and conducted. A sound document process also makes it possible to identify the responsible owner, current version, filing location, approval history, and retention requirement for important records.
What Is The Difference Between A TMF And An Investigator Site File?
A Trial Master File contains essential records needed to document trial conduct and support regulatory review. The sponsor normally maintains the sponsor-side TMF, while investigators and institutions maintain records related to responsibilities performed at the site.The Investigator Site File contains site-level records such as approvals, investigator qualifications, staff documentation, protocol materials, safety communications, and other records needed to show how the trial was conducted locally. The sponsor and investigator files don’t need to contain identical material because their responsibilities differ.
What Are Essential Records In A Clinical Trial?
Essential records are records that help demonstrate how a clinical trial was conducted and whether the resulting information can be considered reliable. They can include protocol documents, approvals, consent materials, monitoring records, investigator qualifications, safety communications, training evidence, trial correspondence, and other records relevant to the specific study.ICH E6(R3) places greater attention on identifying records according to the trial’s design and risks. Teams should therefore determine which records are essential for their study instead of treating document management as a fixed checklist that applies identically to every trial.
What Should An eTMF Audit Trail Record?
An eTMF audit trail should preserve enough information to reconstruct important activity within the electronic system. Depending on the platform, this may include the user, timestamp, record affected, action performed, previous value, new value, metadata change, approval action, deletion event, or permission change.Audit trails also need meaningful review. Study teams should be able to identify unusual changes, unexplained deletions, repeated metadata corrections, or access changes that don’t match normal study activity. Relevant audit information should remain available when records are migrated or archived.
How Often Should Clinical Trial Audit Trails Be Reviewed?
Audit-trail review should follow the risk and importance of the electronic process rather than one fixed review frequency for every system. High-risk activities may need closer review, particularly where changes could affect participant safety, record integrity, approvals, or the reliability of regulated information.The audit-trail review process should state who performs the review, which events matter, how exceptions are investigated, and how findings are documented. Teams should also make sure that review activity itself doesn’t become a mechanical exercise that overlooks meaningful changes.
How Long Should Clinical Trial Documents Be Retained?
There isn’t one retention period that applies to every trial record worldwide. U.S. investigator records for drug investigations can follow requirements linked to marketing approval or discontinuation, while the EU Clinical Trials Regulation generally requires sponsor and investigator TMF content to be retained for at least 25 years after the end of the trial.UK rules also need to be considered, along with national medical-record requirements, study agreements, product-specific regulations, and other obligations. The retention schedule should identify which requirement controls each record category before the organization assigns an archive period or destruction date.
Can Scanned Clinical Trial Documents Replace Original Records?
Scanned documents can sometimes replace original records when the applicable requirements allow it and the copy has been created through a controlled process. The organization needs to confirm that the scanned version accurately represents the original and preserves the information needed to understand the record.The process should also address verification, image quality, metadata, signatures, and the status of the original record. Simply scanning a document into PDF format doesn’t automatically establish that the electronic copy can serve as the retained regulated record.
What Happens To Audit Trails When An eTMF Is Archived Or Migrated?
Relevant audit information should remain available after migration or archival when it’s needed to understand the history of the retained electronic records. Moving only final documents while losing metadata, versions, timestamps, or other required history can weaken the usefulness of the archive.Migration planning should define which records and associated information will move, how transfer accuracy will be checked, and how authorized users will retrieve them later. Testing should confirm that archived records remain readable and can still be interpreted after the original system is retired.
How Can Sponsors And CROs Divide Document Management Responsibilities?
Sponsors can delegate clinical trial activities to CROs or other service providers, but responsibilities need to be clearly documented. Agreements should identify who creates records, who reviews them, where they are filed, how TMF quality is checked, and how records will be transferred when the study or contract ends.Sponsor oversight remains important even when a CRO manages day-to-day TMF activities. The sponsor should have enough visibility to understand document status, unresolved gaps, filing delays, access issues, and transfer risks throughout the study rather than discovering them during final reconciliation.
How Can Clinical Trial Teams Stay Inspection-Ready?
Inspection readiness starts during study conduct. Teams should file essential records on time, maintain correct versions, review document gaps, manage user access, preserve audit information, and confirm that records held outside the main TMF remain accessible through documented locations.Regular TMF and site-file reviews can identify missing approvals, late documents, duplicate versions, incomplete metadata, broken references, or unresolved CRO transfers before they become larger problems. Systems and procedures should allow an authorized reviewer to reconstruct important study activity without depending on explanations from one specific employee.